{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Principal Investigator: Benjamin Maughan, MD, PharmD', 'HUNTSMAN', 'CANCER INSTITUTE', 'UNIVERSITY OF UTAH', 'ACADEMIC: A Randomized Phase II Clinical Trial of ADT', 'Combined with Abiraterone or Docetaxel in Metastatic Hormone', 'Sensitive Prostate Cancer', 'HCI-18-GU-11/Trial ID: HCI115099', 'Coordinating Center', 'Huntsman Cancer Institute', 'Principal Investigator', 'Benjamin L. Maughan MD, PharmD', 'Huntsman Cancer Institute', 'University of Utah', '2000 Circle of Hope', 'Salt Lake City, Utah 84112', 'Email: benjamin.maughan@hci.utah.edu', 'Co-Investigators', 'Abhishek Tripathi MD', 'Stephenson Cancer Center', 'Oklahoma State University', 'Mehmet Bilen MD', 'Winship Cancer Institute', 'Emory University', 'Statistician(s)', 'Ken Boucher, PhD', 'Huntsman Cancer Institute - University of Utah', '2000 Circle of Hope Room 1710', 'Email: Ken.Boucher@hci.utah.edu', 'Medical Monitor', 'TBD', 'Coordinating Center Site', 'Please contact your assigned Clinical Site Monitor and', 'Contact', 'the Clinical Trials Compliance Office', '2000 Circle of Hope', 'Salt Lake City, UT 84112', 'compliance@hci.utah.edu', 'Commercial agents', 'Abiraterone Acetate (Zytiga, Yonsa, or generic),', 'Docetaxel (Taxotere)', 'IND Number', 'N/A', 'NCT Number (CT.gov)', 'NCT03827473', 'Historical Protocol Version Dates', 'Version 1: 09OCT2018', 'Version 2: 13MAR2019']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'TABLE OF CONTENTS', 'Page', 'LIST OF ABBREVIATION', '4', 'PROTOCOL SIGNATURE', '7', 'STUDY SUMMARY', '8', 'SCHEMA', '10', '1', 'OBJECTIVES', '11', '1.1', 'Primary Objective', 'Error! Bookmark not defined.', '1.2', 'Secondary Objectives', '11', '1.3', 'Exploratory Objectives', '11', '2', 'BACKGROUND', '12', '2.1', 'Hypothesis', '12', '3', 'DRUG INFORMATION', '13', '3.1', 'Androgen Deprivation Therapy', '13', '3.2', 'Docetaxel (Taxotere)', '13', '3.3', 'Abiraterone Acetate (Abiraterone)', '15', '4', 'STUDY DESIGN', '19', '4.1', 'Description', '19', '4.2', 'Number of Patients', '19', '4.3', 'Number of Study Centers', '19', '4.4', 'Study Duration', '19', '5', 'ELIGIBILITY CRITERIA', '20', '5.1', 'Inclusion Criteria', '20', '5.2', 'Exclusion Criteria', '21', '5.3', 'Recruitment Strategies', '23', '6', 'RANDOMIZATION', '23', '7', 'TREATMENT PLAN', '23', '7.1', 'Administration Schedule', '23', '7.2', 'Docetaxel', '23', '7.3', 'Zytiga (Abiraterone)', '24', '7.4', 'Concomitant Medications and Therapies', '24', '7.5', 'Duration of Therapy', '25', '8', 'TOXICITIES AND DOSEAGE MODIFICATION', '26', '8.1', 'Dose Modifications and Guidelines for Adverse Event Management', '26', '8.2', 'Supportive Care', '26', '8.3', 'Contraception', '26', '9', 'STUDY CALENDAR', '28', '10', 'STUDY PROCEDURES', '30', '10.1', 'Screening Evaluations', '30', '10.2', 'On Treatment Evaluations', '30', '10.2.2', 'At the time of Progression, if prior to M18 visit', '31', '11', 'CRITERIA FOR EVALUATION AND ENDPOINT', '31', '11.1', 'Safety', '31', '11.2', 'Efficacy', '31', '12', 'STATISTICAL CONSIDERATIONS', '32', 'Page 2 of 52']\n\n###\n\n", "completion": "END"}